Aims: Cannabidiol (CBD) is a cannabis-derived medicinal product with potential application in a wide-variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts.
low risk. 2 There is no evidence for dependency or abuse potential with CBD use, as concluded by the World Health Organisation Expert
Committee on Drug Dependence. 1 The purported effects of CBD include analgesic, anti-inflammatory, antioxidant, anxiolytic, anticonvulsant and cytotoxic effects, which are mediated through signalling mechanisms including the cannabinoid receptor 1 (weak agonist), the cannabinoid receptor 2 (inverse agonist), the serotonin 1a receptor (5-HT 1A ), G protein-coupled receptor 55 (GPR55), G protein-coupled receptor 18 (GPR18) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptors, amongst others. 3 Clinically, CBD is being investigated in multiple disease states including neurodegeneration, anxiety disorder, orphan childhood diseases with a prevalence of <5 in 10 000 individuals (e.g. tuberous sclerosis complex) and addiction (ongoing trials in cannabis and cocaine craving). [4] [5] [6] Epidiolex has recently become the first Food and Hemp-derived CBD is commercially available and is currently used as a health and food supplement commonly for anxiety and pain relief. This market represents a flourishing industry expected to rise financially and globally. 7 However, the blurred lines between CBD as a licensed medicine and CBD as an over-the-counter remedy contribute to the overall lack of understanding of what dose of CBD may be considered therapeutic. This is further hampered by the lack of standardisation in over-the-counter CBD products and their unregulated labelled doses.
Despite the prevalence of CBD use and current hype, guidance on dose recommendations has not advanced and is not clear, additionally hampered by the striking lack of accessible pharmacokinetic and bioavailability data of CBD in humans. 8 No published study to date has reported the absolute oral bioavailability of CBD in humans. 8 Limited dose-determination studies have left a paucity in data surrounding desired plasma concentrations to achieve minimum effective doses. Additionally, the lack of information on the role of different formulations and routes of administration on absorption are also apparent. 
| Eligibility criteria
The titles and abstracts of retrieved studies were examined by 2 independent researchers, and inappropriate articles were rejected.
Inclusion criteria were as follows: an original, peer-reviewed published paper that involved administration of CBD to a clinical population, or reported on clinicaltrials.gov, and included an outcome measurement to assess the efficacy of CBD i.e. improvement in disease. Exclusion criteria were: administration in healthy participants only; CBD administered in combination with other cannabinoids such as with δ- • This review indicates that studies that used higher doses tended to have better therapeutic outcomes compared to lower doses overall.
• This study identifies a strong existing need for doseranging clinical studies to be conducted in which plasma concentrations can provide a better indication of the therapeutic range of cannabidiol.
| Data acquisition and analysis
The included articles were analysed, and the following data extracted: Of the 15 RCTs, the range of doses investigated varied from <1 mg/kg up to 20 mg/kg per day (average 9 mg/kg/d). Significant compared to placebo/control (P < .05) unless stated otherwise.
CBD, cannabidiol; GW, GW Pharmaceuticals; PTSD, post-traumatic stress disorder; RBD, rapid eye movement sleep behaviour disorder; STI, STI Pharmaceuticals; THC, THC Pharm. patients. 20 Likewise, in another double-blind placebo-controlled study, a dose of 6.7 mg/kg reduced subjective anxiety in 10 adults with generalised SAD. 5 Additionally, in a case report in a child, 0.6 mg/kg/d increased sleep quality and duration, and decreased anxiety secondary to PTSD. Analysis of these data revealed that a greater proportion of studies reported a beneficial effect of CBD in the add-on therapy group compared to the monotherapy group (n = 6 and n = 2 respectively).
However, higher doses were used overall within the add-on therapy group compared to the monotherapy group (average 11 and 6 mg/kg/d, respectively) and, due to such a small data set and heterogeneity of studies, we did not perform any further analysis.
| DISCUSSION
To our knowledge, this is the first study to compile and compare all publications in which CBD was administered to clinical populations. 46, 47 ) , neutral results may be secondary to subtherapeutic dosing, and dose-escalation trials with embedded pharmacokinetic studies are the next logical step. 15, 22 Studies in this review using higher doses concluded that CBD was generally well-tolerated with the most frequent side effects including drowsiness, nausea, somnolence, fatigue and vomiting.
Among the clinical trial records retrieved from clinicaltrials.gov, only 60% of completed trials had results uploaded and available. This may represent a significant publication bias and is suggestive of disregard for the priority of publication of negative results, which is a wellrecognised problem. 48 Unfortunately, this may potentially skew the findings presented in this review and so should be interpreted with caution and is acknowledged as a limitation. We also acknowledge that despite all routes of administration being oral, there may be further bias introduced between studies as one dose cannot be directly compared to another due to lack of standardisation of formulations and pharmacokinetic activity, including differences in bioavailability between an oral spray and an oral capsule.
Future studies should also consider the safety of drug interactions with CBD. CBD is a known inhibitor of the cytochrome P450 (CYP) system 49 and can therefore increase plasma concentrations of medicines already in use, in particular antiepileptic drugs. Indeed, this has been reported in a number of publications investigating concomitant use of CBD and antiepileptic drugs. 50 Similarly, CYP inhibitors are predicted to increase CBD plasma concentrations which should be equally monitored. Where possible, further well designed trials with CBD may disentangle whether CBD offers unique therapeutic potential in addition to benefits seen when used as an add-on treatment.
| CONCLUSION
Although larger confirmatory and efficacy clinical trials examining dosing in more detail for each medical context is required, this review summarises that CBD appears to offer a wide-range of activity between 1 and 50 mg/kg/d, and there was a tendency of studies with positive outcomes to have used higher doses of CBD. We recommend pharmacokinetic dosing schedules in subsequent trials to consider this range along with safety data and individual patient requirements. Finally, we implore all completed trial results to be made readily available so the research community can progress and learn from equally important positive and negative outcomes for the ultimate benefit of patients.
